Simon N. Schmidt
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.
Journal: The Lancet. Neurology
Published: December 18, 2025
Vortioxetine in Subgroups of Patients with Major Depressive Disorder and Early-Stage Dementia: Further Results from the MEMORY Study.
Journal: Neuropsychiatric disease and treatment
Published: June 23, 2025
Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.
Journal: Current medical research and opinion
Published: May 15, 2025
Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
Journal: Current medical research and opinion
Published: August 07, 2024
The Functioning Assessment Short Test (FAST): Clinically meaningful response threshold in patients with major depressive disorder receiving antidepressant treatment.
Journal: Journal of affective disorders
Published: March 15, 2024
Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
Journal: Journal of affective disorders
Published: January 29, 2024
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies.
Journal: European child & adolescent psychiatry
Published: October 03, 2023
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Journal: Current medical research and opinion
Published: March 08, 2023
Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
Journal: Journal of affective disorders
Published: March 06, 2023
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
Journal: Journal of psychopharmacology (Oxford, England)
Published: May 02, 2022
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.
Journal: Journal of affective disorders
Published: March 16, 2022
Last Updated: 09/26/2026